Medicines & Healthcare products Regulatory Agency

Ms Charl[redacted]
By Emai[redacted]

Reference[redacted]

30 June 2022

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

+44 (0) 20 3080 6000

gov.uk/mhra

Dear Ms Crichton

COVID-19 Vaccine

Thank you for your e-mail of 01 June 2022 to June Raine on behalf of your support group, UK CV Family, requesting information about what the government and the MHRA have put in place for those who suffer adverse reactions following vaccination.

I am very sorry to hear of the people in your support group's experiences after receiving COVID-19 vaccine.

We continuously monitor the risks and benefits of COVID-19 vaccines and have in place a proactive strategy to do this. We work closely with their public health partners in reviewing the effectiveness and impact of the vaccines to ensure the benefits continue to outweigh any possible side effects. In addition, we work with international counterparts to gather information on the safety of vaccine.

Part of our monitoring role includes continuously reviewing reports of suspected side effects to detect possible new side effects that may require regulatory action. If they have not done so already, we would strongly encourage members of your support group to report their suspected adverse drug reaction to the COVID-19 vaccines through our dedicated Coronavirus Yellow Card website: https://coronavirus-yellowcard.mhra.gov.uk/. These reports provide an important contribution to our monitoring of the safety of the COVID-19 vaccines and medicines.

Our coronavirus (COVID-19) vaccines adverse reactions report is updated weekly with the latest data on Yellow Card reporting with COVID-19 vaccines. This report includes a complete listing of all suspected adverse reactions that have been reported via the Yellow Card scheme for the COVID-19 vaccines.

A Vaccine Damage Payment Scheme is in place however we have no relationship to this scheme. For further details about vaccine damage payments can be found here Vaccine Damage Payment: Overview - GOV.UK (www.gov.uk).

We are committed to the regulation of safe and effective medicines and medical devices. The patient view and experience provides critical information to inform our decisions on the benefits and risks of medical products. Our Patient Involvement Strategy 2021-25 sets out how we will engage and involve the public and patients at every step of the regulatory journey. Our future work includes focussing on listening and supporting patients and strengthening our collaboration with all bodies in

the healthcare system to ensure that the safety changes we advise are embedded without delay in clinical practice.

Should you have any further questions, please do not hesitate to contact: info@mhra.gov.uk

I hope you find this information helpful.

Yours sincerely.

Rebecca
MHRA Customer Experience Centre
Communications and engagement team